Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 20;38(12):1179-1184.
doi: 10.3760/cma.j.cn501120-20211118-00388.

[Research advances on pharmacological interventions for hypertrophic scar]

[Article in Chinese]
L L Shi  1 , M Z Liu  1 , Z Y Jiang  1 , X T Yu  1 , J Q Li  1 , G H Guo  1
Affiliations
Review

[Research advances on pharmacological interventions for hypertrophic scar]

[Article in Chinese]
L L Shi et al. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. .

Abstract
in English, Chinese

Hypertrophic scar is an abnormal fibrous proliferative disease that occurs after deep cutaneous injury, which not only affects aesthetics and function but also has negative psychological effects on the patients. However, the mechanism of hypertrophic scar formation has not been fully elucidated, and its clinical treatment is complex with a high rate of recurrence and no radicle cure. Intervention based on molecular targets will likely be the future direction for the prevention and treatment of hypertrophic scar. In this article, we review the specific roles and mechanisms of drug-targeted interventions in hypertrophic scar formation, including general drugs, cytokines, immunomodulators, herbal extracts, exosomes, and nanomaterials, in the context of advances in both basic and clinical research at home and abroad.

增生性瘢痕是皮肤深层损伤后出现的纤维异常增生性疾病，不但影响美观与功能，还会对患者心理产生不良影响。然而增生性瘢痕的发生机制尚未被完全阐明，其临床治疗复杂且复发率高，尚无确切的根治方法。基于分子靶点的干预，将可能是未来预防和治疗增生性瘢痕的方向。该文结合国内外相关基础研究与临床研究进展，围绕一般药物、细胞因子、免疫调节剂、中药提取物、外泌体、纳米材料等药物靶向干预增生性瘢痕的具体作用和机制进行综述。.

PubMed Disclaimer

Conflict of interest statement

利益冲突 所有作者均声明不存在利益冲突

References

    1. Goverman J, He W, Martello G, et al. The presence of scarring and associated morbidity in the Burn Model System national database. Ann Plast Surg. 2019;82(Suppl 2):S162–168. doi: 10.1097/SAP.0000000000001826. - DOI - PMC - PubMed
    1. Khalid FA, Mehrose MY, Saleem M, et al. Comparison of efficacy and safety of intralesional triamcinolone and combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: randomised control trial. Burns. 2019;45(1):69–75. doi: 10.1016/j.burns.2018.08.011. - DOI - PubMed
    1. Mao XH, Wo Y, He R, et al. Preparation and characterization of different sizes of ethosomes encapsulated with 5-fluorouracil and its experimental study of permeability in hypertrophic scar. J Nanosci Nanotechnol. 2010;10(7):4178–4183. doi: 10.1166/jnn.2010.2207. - DOI - PubMed
    1. Tawfik AA, Fathy M, Badawi A, et al. Topical 5 fluorouracil cream vs combined 5 fluorouracil and fractional erbium YAG laser for treatment of severe hypertrophic scars. Clin Cosmet Investig Dermatol. 2019;12:173–180. doi: 10.2147/CCID.S191137. - DOI - PMC - PubMed
    1. Kim WI, Kim S, Cho SW, et al. The efficacy of bleomycin for treating keloid and hypertrophic scar: a systematic review and meta-analysis. J Cosmet Dermatol. 2020;19(12):3357–3366. doi: 10.1111/jocd.13390. - DOI - PubMed

LinkOut - more resources